Fibrocell Science (NASDAQ:FCSC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday. The brokerage presently has a $0.75 price target on the stock. Zacks Investment Research‘s target price suggests a potential upside of 31.58% from the stock’s previous close.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
Separately, HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Fibrocell Science in a research note on Tuesday, March 6th.
Shares of Fibrocell Science (NASDAQ:FCSC) opened at $0.57 on Tuesday. Fibrocell Science has a 52 week low of $0.51 and a 52 week high of $4.64. The firm has a market capitalization of $12.79, a P/E ratio of -0.31 and a beta of 0.56.
A number of large investors have recently made changes to their positions in FCSC. FNY Partners Fund LP bought a new stake in Fibrocell Science during the 4th quarter valued at approximately $129,000. Parametric Portfolio Associates LLC boosted its stake in Fibrocell Science by 264.0% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 48,259 shares of the company’s stock valued at $194,000 after purchasing an additional 35,000 shares during the period. Anson Funds Management LP acquired a new position in Fibrocell Science in the 4th quarter valued at approximately $287,000. Armistice Capital LLC acquired a new position in Fibrocell Science in the 4th quarter valued at approximately $393,000. Finally, Sabby Management LLC acquired a new position in Fibrocell Science in the 4th quarter valued at approximately $733,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.
WARNING: “Fibrocell Science (FCSC) Rating Increased to Buy at Zacks Investment Research” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/15/fibrocell-science-fcsc-rating-increased-to-buy-at-zacks-investment-research.html.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.